In Vitro Susceptibilities of Yeast Species to Fluconazole and Voriconazole as Determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We conducted active, laboratory-based surveillance for isolates from patients with invasive infections across China from August 2009 to July 2010. DNA sequencing methods were used to define species, and susceptibility to fluconazole and voriconazole was determined by the Clinical and Laboratory Standards Institute M44-A2 disk diffusion method but using up-to-date clinical breakpoints or epidemiological cutoff values.Candida spp. made up 90.5% of the 814 yeast strains isolated, followed by Cryptococcus neoformans(7.7%) and other non-Candida yeast strains (1.7%). Bloodstream isolates made up 42.9% of the strains, isolates from ascitic fluid made up 22.1%, but pus/tissue specimens yielded yeast strains in <5% of the cases. Among the Candida isolates,Candida albicans was the most common species from specimens other than blood (50.1%) but made up only 23% of the bloodstream isolates (P< 0.001).C. parapsilosis complex species were the most common Candida isolates from blood (33.2%). Uncommon bloodstream yeast strains included Trichosporon spp.,C. pelliculosa, and the novel species C. quercitrusa, reported for the first time as a cause of candidemia. Most (>94%) of the isolates of C. albicans,C. tropicalis, and the C. parapsilosis complex were susceptible to fluconazole and voriconazole, as were all of the Trichosporon strains; however, 12.2% of the C. glabrata sensu stricto isolates were fluconazole resistant and 17.8% had non-wild-type susceptibility to voriconazole. Seven C. tropicalis strains were cross-resistant to fluconazole and voriconazole; six were from patients in the same institution. Resistance to fluconazole and voriconazole was seen in 31.9% and 13.3% of the uncommon Candida and non-Candida yeast strains, respectively. Causative species and azole susceptibility varied with the geographic region. This study provided clinically useful data on yeast strains and their antifungal susceptibilities in China.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 1×
“All Candida, Cryptococcus, and other yeast strains recovered from blood; other sterile body fluids, including ascitic fluid and peritoneal dialysate fluid; pus; and tissue from patients with invasive yeast infections (11) were included in this study (Table 1).”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 3×
“Knowledge of local epidemiological patterns is important since epidemiological data may not be generalizable between countries because of geographic variation in epidemiology (30, 32).”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“Fluconazole is an inexpensive, effective antifungal agent often used as first-line therapy of yeast infections (25, 28).”
BackgroundGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“Early and appropriate antifungal therapy is essential for optimum patient outcomes in invasive yeast infections (13, 26).”
BackgroundHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“8% of the cases) was less prevalent than that reported in the United States (24 to 25%) (15, 17) but more so than in certain areas of Latin America and Europe (3 to 8% of the cases) (9, 37).”
BackgroundEmerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811 · cited 2×
“Although invasive candidiasis (IC), including candidemia, remains the most common yeast infection, previously uncommon pathogens such as Trichosporon and Geotrichum species, with reduced susceptibility to antifungal agents, have emerged (23).”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 8×
“Antifungal resistance surveillance programs such as the ARTEMIS Global Antifungal Surveillance Program (1997 to 2007) have been instrumental in monitoring trends in causative species and susceptibility to antifungal agents among pathogenic yeast strains (31, 32).”
BackgroundResultInfluentialHajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294
Cited by
Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
Carolus, H., Pierson, S., Lagrou, K., & Van Dijck, P. (2020) · Journal of Fungi · doi:10.3390/jof6040321 · Cited by 349
Epidemiology of fungal infections in China
Chen, M., Xu, Y., Hong, N., Yang, Y., Lei, W., Du, L., Zhao, J., Lei, X., Xiong, L., Cai, L., et al. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0601-0 · Cited by 137
Self-citationXiao, M., Chen, S. C.-A., Kong, F., Xu, X.-L., Yan, L., Kong, H.-S., Fan, X., Hou, X., Cheng, J.-W., Zhou, M.-L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz573 · Cited by 115
Self-citationBilal, H., Shafiq, M., Hou, B., Islam, R., Khan, M. N., Khan, R. U., & Zeng, Y. (2022) · Virulence · doi:10.1080/21505594.2022.2123325 · Cited by 91
Fan, X., Xiao, M., Liao, K., Kudinha, T., Wang, H., Zhang, L., Hou, X., Kong, F., & Xu, Y.-C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00464 · Cited by 85
Self-citation
Metadata
- Authors
- Wang, H., Xiao, M., Chen, S. C.-A., Kong, F., Sun, Z.-Y., Liao, K., Lu, J., Shao, H.-F., Yan, Y., Fan, H., Hu, Z.-D., Chu, Y.-Z., Hu, T.-S., Ni, Y.-X., Zou, G.-L., & Xu, Y.-C.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2012-12
- Volume
- 50
- Issue
- 12
- Pages
- 3952-3959
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2049661914
- Cited by
- 105
- References
- 14
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro Susceptibilities of Yeast Species to Fluconazole and Voriconazole as Determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. https://app.cochat.ai/papers/10.1128/jcm.01130-12
- The paper
- Wang, H., Xiao, M., Chen, S. C.-A., Kong, F., Sun, Z.-Y., Liao, K., Lu, J., Shao, H.-F., Yan, Y., Fan, H., Hu, Z.-D., Chu, Y.-Z., Hu, T.-S., Ni, Y.-X., Zou, G.-L., & Xu, Y.-C. (2012). In Vitro Susceptibilities of Yeast Species to Fluconazole and Voriconazole as Determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01130-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.